Allogeneic MHC-restricted T-cell receptor (Allo-restricted TCR) (Allo-restricted TCR)

Allogeneic MHC-restricted T-cell receptors (Allo-restricted TCRs) are a specialized class of receptors used in cancer immunotherapy to target tumor-associated antigens (TAAs) with high affinity. In this approach, TCRs are identified from donors whose T cells have not been tolerized to the patient's specific MHC-peptide complexes, allowing for the selection of receptors that bind more strongly to tumor antigens than autologous TCRs (Amir et al., 2011, Blood). These TCRs recognize a specific peptide fragment, such as those from NY-ESO-1 or MAGE-A3, presented by an allogeneic Major Histocompatibility Complex (MHC) molecule on the surface of malignant cells (Wilde et al., 2012, Blood). When expressed in engineered T cells, these receptors trigger a potent cytotoxic immune response upon binding their target, leading to tumor cell apoptosis. While promising for treating various solid and hematological tumors, the use of allo-restricted TCRs requires careful screening to avoid off-target cross-reactivity with healthy tissues and to mitigate the risk of graft-versus-host disease (Stauss et al., 2007, Curr Opin Pharmacol). This technology is often combined with gene-editing techniques to remove endogenous TCRs, thereby improving the safety and specificity of the therapeutic product.

Other names

Allo-HLA-restricted T-cell receptorAllorestricted T-cell receptorAllogeneic MHC-peptide complex recognitionAllo-restricted T-cell recognition

Engineered T-cells express a TCR that binds with high affinity to a specific tumor-associated peptide presented by an allogeneic MHC molecule, triggering the formation of an immunological synapse, T-cell activation, and the release of cytotoxic molecules like perforin and granzymes to induce target cell apoptosis (Amir et al., 2011, Blood).